Teaming up with China as its medical technology and healthcare markets develop
This article was originally published in Clinica
China has prioritised support for medtech as one way of meeting the healthcare needs of its vast and ageing population. But the country's developing industrial and technological strengths should be seen as an opportunity by countries whose medtech industries have traditionally set a strong, and world-leading example. A recent UK DTI Global Watch Mission aimed to illustrate just that for UK companies, by providing contacts and knowledge to help ensure that China's ambitions represent an opportunity for collaboration rather than a threat to future business.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.